In recent years, sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a promising pharmacological innovation initially targeted at glycemic control in type 2 diabetes mellitus (T2DM) (Aguilar-Gallardo et al., 2022). Here, SLC5A2 is linked to diabetes mellitus.